BNTX Form 144 Notice: 500,000 ADS Offered via Goldman Sachs ($56.23M)

Rhea-AI Filing Summary

BioNTech SE (BNTX) Form 144 notice reports a proposed sale of 500,000 American Depositary Shares through Goldman Sachs & Co. LLC with an approximate aggregate market value of $56,230,000 and an approximate sale date of 09/05/2025. The ADS class shows 237,725,735 shares outstanding. The filing states the 500,000 ADS were originally acquired in a private placement on 01/05/2018 from BioNTech SE and paid in cash. The notice also lists multiple prior sales by AT Impf GmbH during the past three months, including transactions on 06/05/2025 (50,000 ADS), 07/10/2025 (40,000 ADS), and several July 2025 dates down to 4,500 and 500 ADS, each with reported gross proceeds. The filer certifies no undisclosed material adverse information.

Positive

• Securities were acquired in a documented private placement and paid in cash on 01/05/2018
• Filer certifies no undisclosed material adverse information
• Broker for the proposed sale is a major, regulated dealer (Goldman Sachs & Co. LLC)

Negative

• Proposed sale is large: 500,000 ADS with aggregate market value of $56,230,000
• Same account (AT Impf GmbH) executed multiple ADS sales in the prior three months, indicating recent disposal activity

Insights

Securities Analyst

TL;DR: A sizeable block of 500,000 ADS (about $56.2M) is being offered by a holder with recent sales activity, which may increase supply of ADS in the market.

The filing documents a proposed sale of 500,000 ADS via Goldman Sachs with an aggregate market value of $56,230,000 and an intended sale date of 09/05/2025. The securities were acquired in a private placement on 01/05/2018 and paid in cash. The same account (AT Impf GmbH) has executed multiple ADS sales across June and July 2025, with transactions ranging from 500 to 50,000 ADS and disclosed gross proceeds for each trade. For investors, the combination of a large single proposed sale and recent patterned disposals by the same seller is a liquidity and supply signal; the filing itself contains no statements about use of proceeds or insider plans beyond the rule 144 representations.

Corporate Governance Expert

TL;DR: This is a routine Rule 144 notice documenting an eligible sale; disclosure appears consistent with procedural requirements.

The Form 144 provides the required disclosure items: identity of broker, number of ADS to be sold, acquisition history showing an arm's-length private placement acquisition, and prior sales in the past three months. The signer affirms absence of undisclosed material adverse information. There are no governance or dilution actions disclosed beyond the sale itself; the filing does not indicate any change in ownership structure or related-party transactions other than the recorded sales activity.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
American Depositary Shares representing ordinary shares, no par value per share	Goldman Sachs & Co. LLC 200 West Street New York NY 10282	500000	56230000	237725735	09/05/2025	NASD

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Ordinary Shares, no par value per share	01/05/2018	Private placement	BioNTech SE			500000	01/05/2018	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
AT Impf GmbH Rosenheimer Platz 6 Munich 2M 81669	American Depositary Shares representing ordinary shares, no par value per share	06/05/2025	50000	5529810
AT Impf GmbH Rosenheimer Platz 6 Munich 2M 81669	American Depositary Shares representing ordinary shares, no par value per share	06/06/2025	4000	440562
AT Impf GmbH Rosenheimer Platz 6 Munich 2M 81669	American Depositary Shares representing ordinary shares, no par value per share	07/08/2025	20000	2228246
AT Impf GmbH Rosenheimer Platz 6 Munich 2M 81669	American Depositary Shares representing ordinary shares, no par value per share	07/10/2025	40000	4483418
AT Impf GmbH Rosenheimer Platz 6 Munich 2M 81669	American Depositary Shares representing ordinary shares, no par value per share	07/23/2025	30000	3409647
AT Impf GmbH Rosenheimer Platz 6 Munich 2M 81669	American Depositary Shares representing ordinary shares, no par value per share	07/24/2025	20000	2285230
AT Impf GmbH Rosenheimer Platz 6 Munich 2M 81669	American Depositary Shares representing ordinary shares, no par value per share	07/25/2025	20000	2288538
AT Impf GmbH Rosenheimer Platz 6 Munich 2M 81669	American Depositary Shares representing ordinary shares, no par value per share	07/28/2025	4500	510242.85
AT Impf GmbH Rosenheimer Platz 6 Munich 2M 81669	American Depositary Shares representing ordinary shares, no par value per share	07/17/2025	500	56000
AT Impf GmbH Rosenheimer Platz 6 Munich 2M 81669	American Depositary Shares representing ordinary shares, no par value per share	07/04/2025	20000	2201066
AT Impf GmbH Rosenheimer Platz 6 Munich 2M 81669	American Depositary Shares representing ordinary shares, no par value per share	07/03/2025	20000	2200466
AT Impf GmbH Rosenheimer Platz 6 Munich 2M 81669	American Depositary Shares representing ordinary shares, no par value per share	07/16/2025	20000	2242486

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the Form 144 for BioNTech (BNTX) disclose?

The filing discloses a proposed sale of 500,000 ADS via Goldman Sachs with an aggregate market value of $56,230,000 and an approximate sale date of 09/05/2025.

Who originally acquired the 500,000 ADS and when?

The 500,000 ADS were acquired in a private placement from BioNTech SE on 01/05/2018 and payment was made in cash on that date.

Has the selling account traded BioNTech ADS recently?

Yes. The filing lists multiple sales by AT Impf GmbH during June and July 2025, including transactions on 06/05/2025 (50,000 ADS) and 07/10/2025 (40,000 ADS).

Who is acting as broker for the proposed sale?

Goldman Sachs & Co. LLC, 200 West Street New York NY 10282 is listed as the broker for the proposed sale.

How many shares outstanding are reported for the ADS class?

237,725,735 ADS outstanding are reported in the filing.